AbbVie makes another small I&I acquisition, buying Nimble for $200M

In an attempt to continue its I&I dominance beyond Humira, Skyrizi and Rinvoq, AbbVie is buying up another small autoimmune startup. The Chicago-area pharma giant is dishing out $200 million upfront in cash to snag ...